Condition: Significant Prostate Cancer · Sponsor: National Taiwan University Hospital
Through a better understanding of the biology of significant (lethal) prostate cancer, we hope to develop new markers/targets from urine metabolomics for more effective screening and prevention of significant prostate cancer. In the meantime, with these new markers we may substantially reduce overtreatment of insignificant PC.
This description comes directly from the study's public registry record.
Chung-Hsin Chen, MD PhD · +886-23123456 · mufasachen@gmail.com
Yeong-Shiau Pu, MD PhD · +886-23123456 · pu5249@ntuh.gov.tw
Always discuss trial participation with your own doctor first.
| Department of Urology, National Taiwan University Hospital | Taipei, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03237702